Northern Trust Corp Aldeyra Therapeutics, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 388,623 shares of ALDX stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
388,623
Previous 385,507 0.81%
Holding current value
$1.97 Million
Previous $1.28 Million 64.11%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$3.19 - $6.32 $9,940 - $19,693
3,116 Added 0.81%
388,623 $2.09 Million
Q2 2024

Aug 14, 2024
SELL
$3.25 - $4.72 $11,960 - $17,369
-3,680 Reduced 0.95%
385,507 $1.28 Million
Q1 2024

May 14, 2024
SELL
$2.77 - $4.22 $10,581 - $16,120
-3,820 Reduced 0.97%
389,187 $1.27 Million
Q4 2023

Feb 13, 2024
SELL
$1.47 - $6.06 $28,572 - $117,788
-19,437 Reduced 4.71%
393,007 $1.38 Million
Q3 2023

Nov 13, 2023
SELL
$6.11 - $8.16 $7,527 - $10,053
-1,232 Reduced 0.3%
412,444 $2.76 Million
Q2 2023

Aug 11, 2023
BUY
$7.11 - $11.89 $2.33 Million - $3.9 Million
328,190 Added 383.91%
413,676 $3.47 Million
Q1 2023

May 15, 2023
SELL
$5.77 - $9.93 $1,875 - $3,227
-325 Reduced 0.38%
85,486 $848,000
Q4 2022

Feb 13, 2023
SELL
$5.08 - $7.09 $50 - $70
-10 Reduced 0.01%
85,811 $597,000
Q3 2022

Nov 14, 2022
SELL
$3.8 - $7.74 $16,457 - $33,521
-4,331 Reduced 4.8%
85,821 $458,000
Q2 2022

Aug 12, 2022
SELL
$2.43 - $4.85 $848,801 - $1.69 Million
-349,301 Reduced 79.49%
90,152 $360,000
Q1 2022

May 13, 2022
SELL
$3.25 - $5.17 $47,651 - $75,802
-14,662 Reduced 3.23%
439,453 $1.95 Million
Q4 2021

Feb 08, 2022
SELL
$3.5 - $9.63 $83,800 - $230,571
-23,943 Reduced 5.01%
454,115 $1.82 Million
Q3 2021

Nov 15, 2021
SELL
$7.94 - $11.31 $198,547 - $282,817
-25,006 Reduced 4.97%
478,058 $4.2 Million
Q2 2021

Aug 13, 2021
BUY
$10.44 - $14.85 $4.31 Million - $6.13 Million
412,862 Added 457.71%
503,064 $5.7 Million
Q1 2021

May 12, 2021
BUY
$6.53 - $14.42 $109,952 - $242,803
16,838 Added 22.95%
90,202 $1.07 Million
Q4 2020

Feb 11, 2021
SELL
$6.31 - $8.13 $12,998 - $16,747
-2,060 Reduced 2.73%
73,364 $504,000
Q3 2020

Nov 16, 2020
BUY
$4.0 - $7.53 $103,208 - $194,289
25,802 Added 52.0%
75,424 $559,000
Q2 2020

Aug 14, 2020
SELL
$1.97 - $5.05 $419,992 - $1.08 Million
-213,194 Reduced 81.12%
49,622 $207,000
Q1 2020

May 14, 2020
BUY
$1.62 - $6.4 $10,594 - $41,856
6,540 Added 2.55%
262,816 $649,000
Q4 2019

Feb 14, 2020
SELL
$4.73 - $7.98 $7,501 - $12,656
-1,586 Reduced 0.62%
256,276 $1.49 Million
Q3 2019

Nov 13, 2019
SELL
$4.41 - $6.12 $168,757 - $234,194
-38,267 Reduced 12.92%
257,862 $1.36 Million
Q2 2019

Aug 13, 2019
BUY
$6.0 - $9.0 $115,218 - $172,827
19,203 Added 6.93%
296,129 $1.78 Million
Q1 2019

May 13, 2019
BUY
$7.14 - $9.85 $115,418 - $159,225
16,165 Added 6.2%
276,926 $2.5 Million
Q4 2018

Feb 12, 2019
BUY
$7.26 - $13.29 $404,229 - $739,973
55,679 Added 27.15%
260,761 $2.16 Million
Q3 2018

Nov 14, 2018
BUY
$6.8 - $14.35 $93,887 - $198,130
13,807 Added 7.22%
205,082 $2.83 Million
Q2 2018

Aug 14, 2018
BUY
$6.95 - $9.18 $994,711 - $1.31 Million
143,124 Added 297.24%
191,275 $1.52 Million
Q1 2018

May 09, 2018
BUY
$6.55 - $8.9 $80,499 - $109,381
12,290 Added 34.27%
48,151 $361,000
Q4 2017

Feb 14, 2018
BUY
$5.7 - $7.75 $105,985 - $144,103
18,594 Added 107.69%
35,861 $244,000
Q3 2017

Nov 13, 2017
BUY
$3.9 - $10.8 $67,341 - $186,483
17,267
17,267 $124,000

Others Institutions Holding ALDX

# of Institutions
117
Shares Held
36.4M
Call Options Held
196K
Put Options Held
142K
View Full List

About Aldeyra Therapeutics, Inc.

ALDX Quotes by TradingView
  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $295M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email